Quadruple P
 Stop or Go?
 Apostel VI
 ECV Implementation
 HTA Longterm conseq.
 HTA Preference study
 HyRAS (Hypitat followup)
 Implementatie Tour
 Triple P
 WOMB study

 Cancer in pregnancy
 Doula study
 ECV tocolysis
 ECV Uterine relaxation
 Keizerlijk litteken
 STAN followup
 VET study
 Wat bevalt beter




Alleviation of Pregnancy Outcome by Suspending of Tocolysis in Early Labour: costs and effects of fibronectin as a triage in women with threatened preterm labour.

Go to the Apostel I website


Fibronectin is an accurate predictor for the occurrence of preterm birth among women with threatened preterm labour. In The Netherlands, at present all women below 32 weeks of gestation with threatened preterm labour are transferred to one in 10 perinatal centres, where they are treated with tocolytics and corticosteroids. The use of fibronectin might be a cost-effective strategy to prevent unnecessary treatment. The APOSTEL-1 study will assess whether testing for fibronectin is a cost-effective strategy that prevents unnecessary treatment in women with threatened preterm labour.

Study design
Multicenter randomized clinical diagnostic trial embedded in a cohort study. All patients will be tested for fibronectin and cervical length at admission. Patients with a cervical length below 10 mm will be treated with tocolysis. Those with negative fibronectin result and a cervical length between 10 – 30 mm will be randomised to tocolysis with nifedepine or to placebo. Patients with a cervical length more than 30 mm (independent of the fibronectin result) will not be treated with tocolysis. The total cohort will be followed.


Study population
Patients with symptoms of preterm labour will be invited to participate in the study.


Inclusion criteria cohort: 

-          Between 24 and 34 weeks of gestation

-          Preterm labour in differential diagnosis

-     Intact membranes


Exclusion criteria cohort:

-          Previous tocolysis treatment for preterm contractions within the previous 7 days

-     Cervical dilation of 4 cm or more at a previous vaginal exam

-         Contra-indications tocolysis or prolongation of pregnancy, e.g.:

        -     Signs of intrauterine infection requiring an intervention

        -          Signs of fetal distress requiring an intervention

        -          Severe maternal disease (HELLP syndrome, eclampsia) requiring an intervention

Patients with a negative fibronectin test and a cervical length between 10 – 30 mm will be invited to participate in a double blind randomized trial between tocolytics (nifedipine) and placebo. Patients with cervical dilation of 4 cm or more and patients with contra-indications for nifedipine will be excluded from randomisation.


Outcome measures
The primary outcome measure is number of days to delivery truncated at 7 days after study entry.

Secondary endpoints are neonatal mortality, neonatal morbidity, maternal morbidity (side effects of tocolysis), costs, and health related quality of life.

Power/data analysis
We propose a non-inferiority effectiveness trial. Based on our pilot study, we anticipate the probability on preterm birth within 7 days in the group of patients with a negative fibronectine test and a cervical length > 10 mm to be 5%. We need 220 patients (110 per arm) to assure with 80% power that the upper limit of the 95% one-sided CI for the difference in the proportion of preterm deliveries < 7 days will be within a prespecified non-inferiority boundary of 7.5%. The results of the randomised clinical trial will be analysed according to the intention to treat principle.

Economic evaluation
The trial results will be combined with data from the prognostic cohort in a model. The average costs and effects of test with fibronectin strategy will be compared using the “treat all” strategy as the reference. Strategies with cervical length measurements will also be assessed. Long term outcomes will be evaluated using modelling.

Time schedule
Start in 2009, duration 3 years.

Project leader
Prof. dr. B.W.J. Mol, gynaecologist and clinical epidemiologist, AMC Amsterdam

Health Technology Assessment and Methodology
Prof. d
r. B.W. Mol, gynaecologist and clinical epidemiologist, AMC Amsterdam

Dr.  B.C. Opmeer, clinical epidemiologist, AMC Amsterdam

ZonMw (

Dossier number: 80-82310-98-09056



Jolande Vis, arts-onderzoeker AMC.

Tel: +31(0)6-49834988

Email: apostel1@studies-obsgyn.nl